'Shut backdoor to WTO', Indian firms warn, as EU seeks free trade concessions
This article was originally published in Scrip
Even as details of the current text in the EU India free trade agreement (FTA) negotiations remain unclear, Indian generic firms say that any attempt to curtail judicial discretion in India or accede to Trade-Related Aspects of Intellectual Property Rights (TRIPs)-plus enforcement and border measures could have serious ramifications for the domestic industry and those dependent on it for generic supplies.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.